Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 967-980

  Goyeneche, Alicia A ^a   Seidel, Erin E ^a   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Antiprogestins; Cyclin dependent kinase 2; Ovarian cancer; p21cip1; p27kip1

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; CASPASE; CYCLIN DEPENDENT KINASE 2; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; STEROID; ULIPRISTAL; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MORPHOLOGY; CELL DEATH; CONCENTRATION RESPONSE; DNA CLEAVAGE; DNA CONTENT; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOSTATIC AGENTS; DNA FRAGMENTATION; ESTRENES; FEMALE; FURANS; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; NORPREGNADIENES; OVARIAN NEOPLASMS;

EID: 84864361258     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9655-z     Document Type: Article

References (52)

1. Spitz IM (2006) Progesterone receptor antagonists. Curr Opin Investig Drugs 7(10):882-890 (Pubitemid 44613715)
2. Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin Pharmac-other9(14): 2459-2472. doi:10.1517/14656566.9.14.2459
3. Benagiano G, Bastianelli C, Farris M (2008) Selective progester-one receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 9(14):2473-2485. doi:10.1517/14656566.9.14.2473
4. Moller C, Hoffmann J, Kirkland TA, Schwede W (2008) Investigational developments for the treatment of progesterone-dependent diseases. Expert Opin Investig Drugs 17(4):469-479. doi:10.1517/13543784.17.4.469 (Pubitemid 351578166)
5. Li D-Q, Wang Z-B, Bai J, Zhao J, Wang Y, Hu K, Du Y-H (2004) Effects of mifepristone on proliferation of human gastric adeno-carcinoma cell line SGC-7901 in vitro. World J Gastroenterol 10 (18):2628-2631 (Pubitemid 39214491)
6. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T (1994) Antitumor effects ofantiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80(3):527-534 (Pubitemid 24073016)
7. Navo MA, Smith JA, Gaikwad A, Burke T, Brown J, Ramondetta LM (2008) In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Phar-macol 62(3):483-489. doi:10.1007/s00280-007-0628-z
8. El Etreby MF, Liang Y, Johnson MH, Lewis RW (2000) Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 42(2):99-106 (Pubitemid 30056641)
9. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL (1997) Antiprogestin inhibition ofcell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11(1):54-66 (Pubitemid 27021254)
10. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV (1998) Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 51(2):149-168 (Pubitemid 28561420)
11. Yokoyama Y, Shinohara A, Takahashi Y, Wan X, Takahashi S, Niwa K, Tamaya T (2000) Synergistic effects of danazol and mifepristone on the cytotoxicity of UCN-01 in hormone-responsive breast cancer cells. Anticancer Res 20(5A):3131-3135
12. Schoenlein PV, Hou M, Samaddar JS, Gaddy VT, Thangaraju M, Lewis J, Johnson M, Ganapathy V, Kallab A, Barrett JT (2007) Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol 31(3):643-655
13. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV (2004) Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 10(15):5215-5225 (Pubitemid 39099796)
14. Liang Y Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV (2003) Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol 23(2):369-380
15. Poole AJ, Li Y Kim Y, Lin SC, Lee WH, Lee EY (2006) Prevention ofBrca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804):1467-1470. doi: 10.1126/science.1 130471 (Pubitemid 44871955)
16. Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P (2009) Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: aninvitroandinvivo study. OncolRep 22(5):1237-1245
17. Rose FV, Barnea ER (1996) Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12 (5):999-1003 (Pubitemid 26104441)
18. Goyeneche AA, Caron RW, Telleria CM (2007) Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin CancerRes 13(11):3370-3379 (Pubitemid 46944925)
19. Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM (2009) Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int 9:4. doi: 10.1186/1475-2867-9-4
20. Freeburg EM, Goyeneche AA, Telleria CM (2009) Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 34(3):743-755
21. Belanger A, Philibert D, Teutsch G (1981) Regio and stereospe-cific synthesis of 11 beta-substituted 19-norsteroids. Influence of 11 beta-substitution on progesterone receptor affinity - (1). Steroids 37(4):361-382. doi:0039-128X(81)90039-8
22. Kloosterboer HJ, Deckers GH, Schoonen WG, Hanssen RG, Rose UM, Verbost PM, Hsiu JG, Williams RF, Hodgen GD (2000) Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 65(10-11):733- 740. doi: 10.1016/S0039-128X(00)001896-6
23. Wiehle RD, Christov K, Mehta R (2007) Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a) anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep 18(1):167-174
24. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T (2005) Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 90(2):953-961. doi:10.1210/jc.2004-1569 (Pubitemid 40279221)
25. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, BlitheDL, BlockerW, Nieman LK(2008) CDB-2914 foruterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 111(5):1129-1136. doi:10.1097/AOG.0b013e3181705d0e (Pubitemid 351620347)
26. Svensson EC, Markstrom E, Shao R, Andersson M, Billig H (2001) Progesterone receptor antagonists Org 31710 and RU 486 increase apoptosis in human periovulatory granulosa cells. Fertil Steril 76(6):1225-1231. doi:S0015-0282(01)02891-6 (Pubitemid 33116391)
27. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK (2003) p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63(21):7081-7088 (Pubitemid 37413443)
28. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52(15):4196-4199
29. Conradie R, Bruggeman FJ, Ciliberto A, Csikasz-Nagy A, Novak B, Westerhoff HV, Snoep JL (2010) Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex. FEBS J 277(2):357-367. doi:10.1111/j.1742-4658.2009.07473.x
30. Yang ES, Burnstein KL (2003) Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 278(47):46862-46868. doi:10.1074/jbc.M306340200 (Pubitemid 37452267)
31. Brown KA, Roberts RL, Arteaga CL, Law BK (2004) Trans-forming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res 6(2):R130-139. doi:10.1186/bcr762
32. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106-130. doi:56/2/106
33. Guarneri V, Piacentini F, Barbieri E, Conte PF (2010) Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol117(2):152-158. doi:10.1016/j.ygyno.2009.11.033
34. Zhao J, Kennedy BK, Lawrence BD, Barbie DA, Matera AG, Fletcher JA, Harlow E (2000) NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 14(18):2283-2297
35. Lents NH, Keenan SM, Bellone C, Baldassare JJ (2002) Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2. J Biol Chem 277(49):47469-47475. doi:10.1074/jbc.M207425200 (Pubitemid 36159264)
36. Flores O, Wang Z, Knudsen KE, Burnstein KL (2010) Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 151(3):896-908. doi: 10.1210/en.2009-1116
37. Sui L, Dong Y Ohno M, Sugimoto K, Tai Y, Hando T, Tokuda M (2001) Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 83(1):56-63 (Pubitemid 32959879)
38. Rosen DG, Yang G, Cai KQ, Bast RC Jr, Gershenson DM, Silva EG, Liu J (2005) Subcellular localization of p27 kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11(2 Pt 1):632-637. doi:11/2/632 (Pubitemid 40116889)
39. Singer JD, Gurian-West M, Clurman B, Roberts JM (1999) Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 13(18):2375-2387 (Pubitemid 29453609)
40. Pajalunga D, Crescenzi M (2004) Regulation of cyclin E protein levels through E2F-mediated inhibition of degradation. Cell cycle (Georgetown Tex) 3(12):1572-1578. doi:1279
41. Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E (2007) Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 102(4):869-877. doi:10.1002/jcb. 21519 (Pubitemid 350036927)
42. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H (1999) p27 (Kip1) ubiquitination and degradation is regulated by the SCF (Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9(12):661-664. doi:S0960-9822(99)80290-5
43. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A (2003) Role of the SCFSkp2 ubiquitin ligase in the degradation ofp21Cip1 in S phase. J Biol Chem 278(28):25752-25757. doi:10.1074/jbc.M301774200 (Pubitemid 36835332)
44. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB (2006) Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 66(7):3754-3763. doi:10.1158/0008-5472.CAN-05-2321
45. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ (2006) CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314(5797):294-297. doi:10.1126/science.1130512 (Pubitemid 44571973)
46. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA (2006) Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. CancerRes 66(16):8219-8226. doi:10.1158/0008-5472.CAN-05-3945 (Pubitemid 44299190)
47. Huang H, Tindall DJ (2007) CDK2 and FOXO1: a fork in the road for cell fate decisions. Cell cycle (Georgetown Tex) 6(8):902-906. doi:4122 (Pubitemid 46658742)
48. Liang Y, Eid MA, El Etreby F, Lewis RW, Kumar MV (2002) Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. Int J Oncol 21 (6):1259-1267
49. Kamradt MC, Mohideen N, Vaughan AT (2000) RU486 increases radiosensitivity and restores apoptosis through mod-ulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 77(1):177-182. doi:10.1006/gyno.1999.5724 (Pubitemid 30217322)
50. Bardon S, Vignon F, Montcourrier P, Rochefort H (1987) Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47(5):1441-1448 (Pubitemid 17023221)
51. Zhou H, Luo MP, Schonthal AH, Pike MC, Stallcup MR, Blumenthal M, Zheng W, Dubeau L (2002) Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther 1(3):300-306. doi:10230130
52. Blumenthal M, Kardosh A, Dubeau L, Borok Z, Schonthal AH (2003) Suppression of the transformed phenotype and induction of differentiation-like characteristics in cultured ovarian tumor cells by chronic treatment with progesterone. Mol Carcinog 38(4):160-169. doi:10.1002/mc.10155 (Pubitemid 37523708)